NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Alto Marketing Ltd

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Safe Intelligent Haematology Auto-validation at Airedale - HORIBA Medical wins second five-year tender for high throughput, routine haematology
Safe Intelligent Haematology Auto-validation at Airedale

 

NewswireTODAY - /newswire/ - Northampton, United Kingdom, 2009/09/29 - HORIBA Medical wins second five-year tender for high throughput, routine haematology.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

One year on from rewarding a new five-year contract to HORIBA Medical for two new ABX Pentra DX 120 haematology analysers and accompanying ABX Pentra ML data management software, Airedale General Hospital has significantly improved auto-validation procedures for haematology results. With over 60% of all results now being safely and intelligently validated automatically, this has freed up staff time significantly, whilst also improving turnaround times and service levels.

In reviewing its requirements for new routine haematology analysers, the pathology laboratory at Airedale General Hospital recognised the need to implement smooth working practices in order to ensure the best use of valuable staff time. IT-based solutions ensuring efficient data management and subsequent automatic results validation were considered a key differentiator in the Trust’s tender selection process.

“Having already been working with HORIBA Medical for a number of years, we were very impressed by the reliable work horse solutions that our previous ABX Pentra high throughput haematology analysers had proven to be. In addition, HORIBA Medical (horiba.com) has also always provided us with an excellent level of customer service and training support,” explained Dr Afruj Ali Ruf, Consultant Healthcare Scientist. “We did now however need a greater degree of data management support and the ABX Pentra ML was the most flexible data manager that we had seen, giving us the greatest scope to safely develop our auto-validation capabilities.”

Adapting the ABX Pentra ML to meet the specific requirements at Airedale was a relatively simple process since the Hospital had already developed basic rules based validation with the previous system. “Having already established our groupings of normal blood count ranges, such as for pregnant and post operative patients based on our historical data, we were able to confidently and quickly implement intelligent auto-validation procedures using the ABX Pentra ML,” continued Dr Ruf. “The ABX Pentra ML was very simple to configure to recognise such groupings and apply the necessary normal ranges.”

The ability to easily develop rules based on certain clinical details, clinicians, or even samples from a certain location, as well as good IT links to haematology clinics has meant that the majority of results can now be delivered in real time. Faster turnaround times (TATs) have improved levels of service for patients who may have had to travel long distances to attend clinics. Airedale covers the greatest geographical area of all UK NHS Trusts and encompasses three Primary Care Trusts crossing the Yorkshire/Lancashire border!

“Now that we have our normal ranges confidently established within the ABX Pentra ML, our auto-validation procedures now only ever intelligently flag truly abnormal results. This gives our experienced staff more time to proactively investigate these further to provide more in depth clinically relevant results,” added Dr Ruf. “Having already achieved a 60% auto-validation rate is fantastic, but we know that we can work with HORIBA Medical to make our ABX Pentra ML work even harder for us. Since our staffing levels are finite but our workload isn’t, we’re now looking to develop further rules.”

In addition to the two ABX Pentra ML validation stations in the main laboratory, a satellite ABX Pentra ML validation station has also been installed remotely from the routine laboratory, next to the microscopes used for the examination of blood films. This means that comments on blood films made for abnormal samples can be typed and uploaded directly to the LIMS. This not only enables sample validation at the site of the microscope to further increase TATs, but it also minimises opportunity for transcription errors. In addition, it also assists workflow since laboratory personnel always know exactly at which stage in the analytical process a sample is.

“All of this workflow enhancement really can only be achieved with a readily configurable data management system and a company happy to work in partnership with us, both of which we have found in the ABX Pentra ML and HORIBA Medical,” concluded Dr Ruf. “Having such a flexible data management system is really helping us towards ‘LEANing’ our result validation process.”

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Alto Marketing Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Safe Intelligent Haematology Auto-validation at Airedale

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Leigh Dilley - Alto-Marketing.com 
+44(0)14 8955 7672 catherines[.]alto-marketing.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Alto Marketing Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Alto Marketing Ltd / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

SCHOTT Pharma Launches EVERIC® Lyo & Amber Vials for Light-sensitive ADCs
Arbitration Tribunal Upholds Ipsen’s Termination of R&D Agreement with Galderma
New Data Reinforces Ipsen’s Commitment to Bringing Solutions and Addressing Care Gaps in Neurological Diseases At TOXINS
Opdivo® Intravenous Infusion Approved in Taiwan in Combination with Yervoy® for the Treatment of Adult Patients
U.S. FDA Grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in First Line Unfit Acute Myeloid Leukemia
Additional Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer in South Korea
BostonGene Recognized by Frost & Sullivan for 2025 Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions
Ipsen Expands Early Development Pipeline with Simcere Zaiming’s Innovative Antibody Drug Conjugate
Ipsen Update on Phase II FALKON Trial in Patients with Ultra-rare Bone Disease, Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen Completes Acquisition of ImCheck Therapeutics, Expanding Oncology Pipeline
NEC Presents Phase I Results for Personalized AI-Powered Oral Cancer Vaccine NECVAX-NEO1 at ESMO Immuno-Oncology Congress 2025
Ono Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera
JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information
Ono Receives Supplemental Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer
WuXi AppTec Receives Frost & Sullivan’s 2025 Global Company of the Year Recognition in the CRDMO Industry

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2005-2026 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)